[1] Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6.
[2] WHO Drug Information. International Nonproprietary Names for Pharmaceutical
[3] Feng Y, et al. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer[J]. Acta Pharmaceutica Sinica B, 2024.
[4] Kurochkina Y, et al. POS0673 TOLEROGENIC DENDRITIC CELLS IN RHEUMATOID ARTHRITIS PATIENTS: NEWS AND PROMISES[J]. 2021.
[5] Kalliolias GD, et al. Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update. Biomedicines. 2024 Jan 9;12(1):138. DOI:
10.3390/biomedicines12010138[6] Ammann S, et al., Pyrrolo[1,2-b] pyridazine derivatives. WO2020014468A1.